

No.: *186*/TB-DPTU2

Hanoi, June *26*, 2026

Re: ~~Report on the shareholder structure of Central
Pharmaceutical Joint Stock Company No. 2 failing to
meet public company conditions~~



NOTICE

On the company no longer meeting public company conditions

To: - State Securities Commission of Vietnam
- Hanoi Stock Exchange

Firstly, Central Pharmaceutical Joint Stock Company No. 2 would like to sincerely thank your Agency for the attention and support extended in recent times.

In implementation of the provisions of Articles 32, 38, and 39 of the 2019 Securities Law, as amended and supplemented by Law No. 56/2024/QH15 dated November 29, 2024; and Article 8 of Circular No. 19/2025/TT-BTC dated May 5, 2025 of the Ministry of Finance on the registration of public companies, revocation of public company status, and reporting on audited contributed charter capital.

Central Pharmaceutical Joint Stock Company No. 2 hereby announces that the company no longer meets the conditions for a public company stipulated in Clause 11, Article 1 of Law No. 56/2024/QH15 dated November 29, 2024, amending and supplementing Point a, Clause 1, Article 32 of Securities Law No. 54/2019/QH14 dated November 26, 2019, specifically as follows:

- The shareholder structure of Central Pharmaceutical Joint Stock Company No. 2 (based on the Consolidated List of Securities Holders Exercising Rights No. VNMEETVSDD013219/VSDDP2XX, prepared by the Vietnam Securities Depository and Clearing Corporation on March 19, 2026), is as follows:

Shareholder type	Number of shareholders	Number of shares	Ownership ratio of voting shares	Ownership ratio of issued shares
Major shareholders	3	18,831,450	94.16%	94.16%
Shareholders other than major shareholders	411	1,168,550	5.84%	5.84%
Total	414	20,000,000	100%	100%

Thus, Central Pharmaceutical Joint Stock Company No. 2 has not met the conditions for a public company as stipulated in Point a, Clause 1, Article 32 of Securities Law No. 54/2019/QH14, as amended and supplemented by Point a, Clause 11, Article 1 of Law No. 56/2024/QH15, specifically: *it does not ensure a minimum of 10% of voting shares being held by at least 100 investors that are not major shareholders.*

The Company respectfully notifies the State Securities Commission of Vietnam and the Hanoi Stock Exchange for their information and acknowledgment.

Central Pharmaceutical Joint Stock Company No. 2 undertakes to continue fully performing its obligations related to public company status until the State Securities Commission issues an official decision on the termination of its public company status



in accordance with current applicable law.
We sincerely thank you./.

- Recipients:
- *As above*
- *Archive: the Company*

**LEGAL REPRESENTATIVE
CHAIRMAN OF THE BOARD OF
DIRECTORS
Signed**

Cao Tien Dung



No.: *187*/CBTT-DPTU2

Hanoi, June *26*, 2026



EXTRAORDINARY INFORMATION DISCLOSURE

To: - State Securities Commission of Vietnam
- Hanoi Stock Exchange

1. Organization name: Central Pharmaceutical Joint Stock Company No. 2
 - Ticker symbol: DP2
 - Address: No. 9 Tran Thanh Tong Street, Hai Ba Trung Ward, Hanoi.
 - Tel: 024 39716579/91: Fax: 024 35251484.
 - Email: dopharma@dopharma.com.vn.
 - Website: www.dopharma.com.vn _ dopharma.vn

2. Content of disclosed information:

Central Pharmaceutical Joint Stock Company No. 2 (the “Company”) hereby announces that the Company no longer meets the conditions for a public company stipulated in Clause 11, Article 1 of Law No. 56/2024/QH15 dated November 29, 2024 on amending and supplementing Point a, Clause 1, Article 32 of Securities Law No. 54/2019/QH14 dated November 26, 2019 (enclosed with Document No. *186*/TB-DPTU2 dated June *26*, 2026)

This information was published on the Company’s website on June *26*, 2026 at the following link: www.dopharma.com.vn _ dopharma.vn

We hereby undertake that the information disclosed above is truthful, and we take full responsibility under the law for the content of the disclosed information/

Recipients:

- As above
- Archive: the Company

Representative of the organization
Legal Representative/Person Authorized to Disclose
Information
(Signature, full name, title, and seal)
CHAIRMAN OF THE BOARD OF DIRECTORS
Signed

Cao Tien Dung